Compare Cardinal Health Inc (CAH) vs Mercadolibre Inc (MELI) Price & Performance

Cardinal Health (CAH) trades at $235.3, down 0.79% on the day, but remains near its 52-week high. The stock exhibits a bullish technical signal with consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue for fiscal 2025 was $222.58 billion, with net income reaching $1.56 billion. Analyst consensus is strongly positive, with 18 buys and a $266.43 price target, reflecting confidence in the company's pharmaceutical and specialty business growth.

The outlook for CAH is favorable, driven by robust earnings performance and optimistic fiscal 2027 guidance. Key opportunities include sustained demand for specialty drugs and operational efficiency gains. Risks involve high debt levels, with a debt-to-asset ratio of 16.09 in 2025, and competitive pressures in the healthcare distribution sector. Investors should weigh strong analyst support against balance sheet leverage and market volatility.

MercadoLibre (MELI) trades at $1,876, up 2.83% today, with strong technical momentum and bullish moving average signals. The company reported Q2 2026 EPS of $9.19, beating estimates, while revenue grew 50% year-over-year to exceed $10 billion for the first time. Analyst consensus remains strongly bullish with 23 buy ratings and a $2,150 price target, though margin compression from strategic investments has tempered near-term profit growth.

MELI's growth-first strategy is driving market share gains but pressuring margins, creating a tension between rapid expansion and profitability. The stock offers significant upside to analyst targets but faces execution risks from increased competition and macroeconomic volatility in Latin America. Long-term investors may find value in the ecosystem growth, while short-term volatility could persist amid margin concerns.